Ningbo, China (Press Release) – Ningbo NewBay Medical Technology Co., Ltd., a sub­sid­i­ary of Ningbo Tai Kang Medical Technology Co., Ltd. announced today that it has entered into a licensing agree­ment with Genentech, a member of the Roche Group, under which it has been granted the ex­clu­sive global rights to further de­vel­op and com­mer­cial­ize GDC-0570, a small molecule Pan-PIM in­hib­i­tor that is active against multiple myeloma and prostate cancer in pre­clin­i­cal models. PIM kinases regulate cell metabolism, growth and sur­vival.

“We are very pleased to enter this global ex­clu­sive license agree­ment with Genentech. …